OrganOx Limited

OrganOx Limited is a medical device company specializing in organ preservation technology for transplantation. The company develops and manufactures the OrganOx metra® platform, which uses normothermic machine perfusion (NMP) technology to extend organ preservation times outside the body. The metra® system maintains organs at near-physiologic conditions, enabling clinicians to preserve donor livers for up to 12 hours (or 24 hours in certain regions) compared to conventional static cold storage methods. This extended preservation window allows transplant centers to better assess organ viability, reduce organ discard rates, optimize surgical scheduling, and improve transplant outcomes. The technology addresses critical challenges in organ transplantation by reducing wait times and enhancing procedural planning. OrganOx also conducts research into treating diseased organs and developing technologies to potentially decrease future transplant demand. The company was acquired by Terumo Corporation in October 2025, positioning it within a global medical device conglomerate while maintaining independent operations. Products have received FDA approval, including recent clearance for operation during air transport. OrganOx serves transplant centers and research institutions globally, with a focus on liver transplantation applications.